Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807486 | 0.95 | APP (0.53) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL8805777 | 0.93 | APP (0.54) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL31570769 | 0.93 | APP (0.54) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL7455570 | 0.89 | APP (0.60) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL7022072 | 0.86 | FAAH (0.56) | APPMTNR1AMTNR1BFAAHKMT2A | |
| SCHEMBL10660855 | 0.84 | TSHR (0.58) | APPMTNR1AMTNR1BFAAH | |
| SCHEMBL1428483 | 0.84 | KDM4E (0.56) | APPMTNR1AMTNR1BCHRNB2CHRNA4 | |
| SCHEMBL15965349 | 0.84 | APP (0.53) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL5957100 | 0.84 | MTNR1A (0.53) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL595463 | 0.84 | APP (0.53) | APPMTNR1AMTNR1BFAAHCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856749-B1 | WATER-SOLUBLE, NON-AGGREGATED SILICON PHTALGCYANINE COMPOUND HAVING IN VITRO ANTICANCER EFFECT AGAINST CANCER TYPES OF LUNG, LIVER, BREST AND MELANOMA | KARADENIZ TEKNIK UNIV (TR) | 2024-05-01 | — | — | EP | claimed |
| EP-3856749-B1 | WATER-SOLUBLE, NON-AGGREGATED SILICON PHTALGCYANINE COMPOUND HAVING IN VITRO ANTICANCER EFFECT AGAINST CANCER TYPES OF LUNG, LIVER, BREST AND MELANOMA | KARADENIZ TEKNIK UNIV (TR) | 2024-05-01 | — | — | EP | disclosed |
| EP-3856749-A1 | WATER-SOLUBLE, NON-AGGREGATED SILICON PHTALGCYANINE COMPOUND HAVING IN VITRO ANTICANCER EFFECT AGAINST CANCER TYPES OF LUNG, LIVER, BREST AND MELANOMA | Karadeniz Teknik Universitesi (TR) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068015-A1 | WATER-SOLUBLE, NON-AGGREGATED SILICON PHTALGCYANINE COMPOUND HAVING IN VITRO ANTICANCER EFFECT AGAINST CANCER TYPES OF LUNG, LIVER, BREST AND MELANOMA | KARADENIZ TEKNIK UNIVERSITESI (TR) | 2020-04-02 | — | — | WO | disclosed |
| US-6627648-B1 | Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives | TARGACEPT, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | APP 490/4885MTNR1A 236/4885MTNR1B 237/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | APP 325/4885MTNR1A 252/4885MTNR1B 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.